Literature DB >> 12079788

Assembly of p-selectin ligands on a polymeric template.

Tatyana V Pochechueva1, Oxana E Galanina, Michael I Bird, Nikolay E Nifantiev, Nicolai V Bovin.   

Abstract

High-affinity receptor-ligand interactions frequently involve molecular interactions at two distinct sites. A derivatized polyacrylic-based polymer was synthesized to allow substitution with multiple ligands (e.g., L(1) and L(2)) on the backbone. Two-site P-selectin-ligand interactions were first studied with SiaLe(x) (L(1)) and tyrosine sulfate (L(2)) covalently incorporated onto the flexible polymer. In competition assays, a marked synergistic inhibitory effect was observed when the polymer presented both L(1) and L(2) as opposed to either ligand alone. In a second approach, the SiaLe(X) ligand was reduced in complexity so that L(1) was fixed as Le(x) or Le(a), and alternative L(2) groups (to mimic sialic acid) were investigated. Certain combinations of L(1) and L(2) were better antagonists of P-selectin than SiaLe(x) itself. These approaches offer the potential of facilitating the discovery of novel inhibitors of receptors or enzymes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079788     DOI: 10.1016/s1074-5521(02)00157-6

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  3 in total

1.  Polymer-Based Therapeutics.

Authors:  Shuang Liu; Ronak Maheshwari; Kristi L Kiick
Journal:  Macromolecules       Date:  2009-01-13       Impact factor: 5.985

2.  Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease.

Authors:  Alison E John; Nicholas W Lukacs; Aaron A Berlin; Aiyappa Palecanda; Robert F Bargatze; Lloyd M Stoolman; Jon O Nagy
Journal:  FASEB J       Date:  2003-10-16       Impact factor: 5.191

3.  Uncharged P-selectin blockers.

Authors:  T V Pochechueva; O E Galanina; N A Ushakova; M E Preobrazhenskaya; M A Sablina; N E Nifantiev; Yu V Tsvetkov; Ya V Vozney; A Imberty; N V Bovin
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.